Investment themes
1. Commercial presence in the US with extensive synergies
One of the key strategic priorities for growth is to capitalize on the company’s commercial position in the US. Orexo’s US subsidiary, Orexo US Inc., has long experience in pricing and reimbursement, sales and marketing, RWE clinical trials, focusing on one of the largest health crises in the US in modern times – opioid use disorder (OUD). Today Orexo is commercializing Zubsolv® for OUD and the digital support program MODIA®. Adding additional products to the US commercial platform offers significant synergistic benefits.
2. Strong cash generation from the US Commercial segment
Orexo’s lead drug Zubsolv is an important cash generator. In 2024, EBITDA for US Commercial, which is entirely related to Zubsolv sales, amounted to SEK 177 million. Revenue from Zubsolv is an important addition to the operation of the business.
3. AmorphOX unlocks a broad range of new opportunities in the development of innovative drugs
Orexo’s next-generation drug delivery technology is an innovative powder-based technology that is rapidly dissolving while also being chemically and physically stable, allowing for improved handling and storage of drugs based on an amorphous structure. With the introduction of AmorphOX®, Orexo is meeting the challenges of delivering small molecules, peptides and biologics previously thought to be impossible to formulate for alternative routes of administration.
4. AmorphOX paves the way for continued pipeline growth
AmorphOX is a scalable technology as it works with different active substances, dosage forms and routes of administration. AmorphOX is used in the drug candidates OX124 (registration phase), OX125 and OX640 (clinical stage) and will be the backbone in the future development of new innovative drugs targeting large unmet needs.
5. Entering partnership for development and commercialization of drugs that goes beyond OUD
Seek collaborations with partners where their molecules can benefit from the unique properties of the AmorphOX technology and/or for the development and commercialization of drugs that goes beyond Orexo’s core therapeutic area of OUD.
